In recent years, impressive advances in the knowledge about a vast number of microbes living in the human body and interactions between the microbiota and the human body have been observed. All micro-organisms that live in the human body consist of around 10 ^ 14 cells. The number of microbial cells colonizing the human body is ten times higher than the number of its own cells and the weight of all micro-organisms is about 2-2.5 kg. The number of bacterial genes is 50-100 times greater than the number of genes in the human body. Nowadays, the human microbiota is often regarded as a “newly discovered organ” or even as a “supergenome”. The results of many studies have revealed that disruption of the bowel microecosystem may affect the development of irritable bowel syndrome (IBS) symptoms. Therefore, manipulation of the gut microflora was hoped to be a new tool in the treatment of this disease. Various methods (probiotics, prebiotics, antibiotic therapy, transplantation of faecal flora) have been used to modify the intestinal microbiota by supporting the expansion of bacteria considered beneficial and reducing the number of those regarded as harmful, thus alleviating the IBS symptoms. There is much evidence in the literature to suggest that the intestinal microbiota and the gut-intestinal axis are important factors in the pathogenesis of IBS. Moreover, the literature findings have demonstrated beneficial effects of modifying the intestinal flora composition in alleviating IBS symptoms. Although the pathophysiology of IBS and the role of the intestinal microflora and gut-intestinal axis in it are well known, many issues are still to be elucidated. Further research into the bacteria identified in stool and colon mucosa of healthy individuals should provide more information on restoration of intestinal homeostasis in IBS patients.
展开▼
